Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Evidence grades (based on the previous guideline version [1])

From: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

A Randomized, double-blind clinical trial of high quality (for example, sample-size calculation, flow chart of patient inclusion, intention-to-treat (ITT) analysis, sufficient sample size)

B Randomized clinical trial of lesser quality (for example, only single-blind, limited sample size: at least 15 patients per study arm)

C Comparative trial with severe methodological limitations (for example, not blinded, very small sample size, no randomization) or large retrospective observational studies.

D Adapted from existing consensus document or statement based on expert opinion voting during consensus conference

Back to article page

World Allergy Organization Journal

ISSN: 1939-4551

Contact us